Itopride hydrochloride efficacy in the management of delayed gastric emptying in type 1 diabetis mellitus patients in the presence of autonomic neuropathy
Aim. Evaluation of the itopride (Ganaton?, Abbot) therapy efficacy in the management of gastrointestinal (GI) symptoms and gastric motor function (GMF) in type 1 diabetis mellitus (T1DM) patients (pts) in the presence of GMF dysfunction and other forms of diabetic autonomic neuropathy (DAN). Materi...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6bb25c7caf804a2d8692ec707221cf9f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Aim. Evaluation of the itopride (Ganaton?, Abbot) therapy efficacy in the management of gastrointestinal (GI) symptoms and gastric motor function (GMF) in type 1 diabetis mellitus (T1DM) patients (pts) in the presence of GMF dysfunction and other forms of diabetic autonomic neuropathy (DAN). Materials and Methods. The total of 34 patients with T1DM, GMF dysfunction and DAN were selected for randomized, prospective, open-label, comparative study. The duration of the study was 6 weeks. The study group (17 pts) received itopride 150 mg total daily. The control group (17 pts) did not receive any treatment for GMF. А questionnaire was used for the assessment of gastrointestinal (GI) symptoms. Gastric emptying velocity was evaluated with 13C-octanoate breath test. Results. As a result of itopride therapy there was a statistically significant decrease in the amount of time (T1/2) needed for the gastric emptying. The median amount of time decreased from 89.0 [82.3; 101.0] min to 53.0 [82.3; 101.0] min (p |
|---|